All In Biotech

Drug Trial Radar · NCT00972777

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

Last checked: Nov 20, 2026Latest source record: Mar 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 474 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

474

Actual

Start

Oct 2009

Primary completion

Oct 2010

Study completion Feb 2011

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Sep 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.

Conditions

  • Bacterial Conjunctivitis

Interventions

  • BesifloxacinDrug

    Besifloxacin 0.6% administered into the study eye two times a day for three days.

  • Vehicle (Placebo)Drug

    Vehicle administered to the study eye two times a day for three days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical ResolutionTime frame: Visit 2
  2. Microbial EradicationTime frame: Visit 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb Incorporated

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.